Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11–13 weeks
Open Access
- 15 March 2010
- journal article
- research article
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 35 (6), 662-670
- https://doi.org/10.1002/uog.7628
Abstract
Objective To examine the performance of screening for pre-eclampsia (PE) and gestational hypertension (GH) by a combination of maternal factors and various biophysical and biochemical markers at 11–13 weeks' gestation. Methods This was a case–control study of 26 cases of early PE, 90 of late PE, 85 of GH and 201 unaffected controls. Maternal history was recorded, the uterine artery with the lowest pulsatility index (L-PI) and mean arterial pressure (MAP) were measured and stored plasma and serum were analyzed for placental growth factor (PlGF), inhibin-A, activin-A, tumor necrosis factor receptor-1, matrix metalloproteinase-9, pentraxin-3 and P-selectin. Results Multivariate logistic regression analysis demonstrated that significant prediction for early PE was provided by maternal factors, MAP, uterine artery L-PI and serum PlGF. Significant prediction of late PE was provided by maternal factors, MAP, uterine artery L-PI, PlGF, activin-A and P-selectin. For GH significant prediction was provided by maternal factors, MAP, uterine artery L-PI and activin-A. In screening by a combination of maternal factors, biophysical and biochemical markers the estimated detection rates, at a 5% false-positive rate, were 88.5% (95% CI, 69.8–97.4%) for early PE, 46.7% (95% CI, 36.1–57.5%) for late PE and 35.3% (95% CI, 25.2–46.4%) for GH. Conclusion Combined biophysical and biochemical testing at 11–13 weeks could effectively identify women at high risk for subsequent development of hypertensive disorders in pregnancy. Copyright © 2010 ISUOG. Published by John Wiley & Sons, Ltd.Keywords
This publication has 34 references indexed in Scilit:
- Maternal Plasma P-selectin at 11 to 13 Weeks of Gestation in Hypertensive Disorders of PregnancyHypertension in Pregnancy, 2010
- Maternal plasma pentraxin 3 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancyPrenatal Diagnosis, 2009
- First-Trimester Prediction of Early PreeclampsiaHypertension, 2009
- First‐trimester maternal serum matrix metalloproteinase‐9 (MMP‐9) and adverse pregnancy outcomePrenatal Diagnosis, 2009
- Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsiaUltrasound in Obstetrics & Gynecology, 2008
- Prediction of pre‐eclampsia by uterine artery Doppler imaging: relationship to gestational age at delivery and small‐for‐gestational ageUltrasound in Obstetrics & Gynecology, 2008
- Uterine vein and maternal urinary levels of activin A and inhibin A in pre‐eclampsia patientsClinical Endocrinology, 2006
- Practice bulletin #33: diagnosis and management of preeclampsia and eclampsiaPublished by Ovid Technologies (Wolters Kluwer Health) ,2002
- Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study Pre-eclampsia and cardiovascular disease later in life: who is at risk?BMJ, 2001
- The Placental BedHypertension in Pregnancy, 1996